NCT04908033

Brief Summary

The main goal of the project is to prove that ultra-high-frequency ECG (UHF-ECG) can be used as a diagnostic tool that allows the prediction of patients susceptible to the negative effect of right ventricular myocardial pacing. The prediction will be based on the assessment of electrical dyssynchrony and local depolarization durations of left ventricular depolarization emerging during right ventricular pacing. If proved to be valid in left ventricular negative remodeling prediction, UHF-ECG-derived parameters of ventricular dyssynchrony could be used as markers allowing a lead placement optimization during an implant procedure. This information can help the operator to identify patients with the urgent need for physiological pacing (HB or LBBp) and patients in which a right ventricular myocardial pacing is sufficient and will not lead to the development of the negative left ventricular remodeling.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
368

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2021

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

May 15, 2021

Completed
17 days until next milestone

First Posted

Study publicly available on registry

June 1, 2021

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

March 5, 2025

Status Verified

March 1, 2024

Enrollment Period

4.1 years

First QC Date

May 15, 2021

Last Update Submit

March 3, 2025

Conditions

Keywords

myocardial pacingphysiological pacingnegative remodelingdyssynchronyultra-high-frequency ECG

Outcome Measures

Primary Outcomes (1)

  • negative remodeling prediction

    * 5% drop in the left ventricular ejection fraction will be predicted by the duration of UHF-ECG electrical dyssynchrony parameter * 5% drop in the left ventricular ejection fraction will be predicted by the duration of UHF-ECG left ventricular lateral wall delay parameter * 5% drop in the left ventricular ejection fraction will be predicted by the duration of UHF-ECG V6d parameter * 10% drop in the left ventricular ejection fraction will be predicted by the duration of UHF-ECG left ventricular lateral wall delay parameter * 10% drop in the left ventricular ejection fraction will be predicted by the duration of UHF-ECG V6d parameter

    1 year from randomization

Secondary Outcomes (2)

  • RV myocardial to physiological pacing comparison

    2 years from randomization

  • UHF-ECG prediction of clinical outcome

    3 years from randomization

Study Arms (2)

myocardial pacing group

patients with the pacing lead placed into the right ventricle to obtain myocardial capture

Device: pacemaker implantation

physiological pacing group

patients with the pacing lead placed into the His bundle or left bundle branch area

Device: pacemaker implantation

Interventions

pacemaker implantation

myocardial pacing groupphysiological pacing group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

360 patients with an indication for permanent pacing due to permanent conduction disease of/below the AV node

You may qualify if:

  • expectation of permanent right ventricular pacing with atrio-ventricular delay set to 150/180 ms (130/160 resp.) for sensed/paced atrial events during a follow-up,
  • a good quality of images during echocardiography,
  • willingness to attend clinical check-ups in the implanting center for at least two years.
  • life expectancy of at least 2 years

You may not qualify if:

  • planned cardiac surgery or transcatheter aortic valve implantation
  • hypertrophic cardiomyopathy
  • an indication for implantable cardioverter-defibrillator, biventricular implantable cardioverter-defibrillator, or biventricular pacemaker
  • active myocarditis
  • cardiac surgery or coronary revascularization in the last ten days
  • persistent/permanent atrial fibrillation during randomization
  • severe aortic stenosis
  • mitral valvular disease with an indication to intervention.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Karol Curila

Prague, 10000, Czechia

Location

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

May 15, 2021

First Posted

June 1, 2021

Study Start

May 1, 2021

Primary Completion

June 1, 2025

Study Completion

December 1, 2025

Last Updated

March 5, 2025

Record last verified: 2024-03

Locations